Products
Research Areas
COVID-19
Resources
Login
Quick Order
Cart
Login
Registration enables users to use special features of this website, such as past
order histories, retained contact details for faster checkout, review submissions, and special promotions.


Fields marked with a * are required.

Login
Quick Order
Contact Us

Locations


Orders Processing,
Shipping & Receiving,
Warehouse

2 Shaker Rd Suites
B001/B101
Shirley, MA 01464


Production Lab

Floor 6, Suite 620
20700 44th Avenue W
Lynnwood, WA 98036

Telephone Numbers



Tel: +1 (206) 374-1102
Fax: +1 (206) 577-4565

Contact Us



Additional Contact Details

Login
Registration enables users to use special features of this website, such as past
order histories, retained contact details for faster checkout, review submissions, and special promotions.


Fields marked with a * are required.

Login
Quick Order
Catalog Number Size Price
LS-B2858-0.1 0.1 mg (1 mg/ml) $460 
HLA-DRA Antibody - Human Small Intestine: Formalin-Fixed, Paraffin-Embedded (FFPE)
HLA-DRA Antibody - Human Thymus: Formalin-Fixed, Paraffin-Embedded (FFPE)
HLA-DRA Antibody - Human Kidney: Formalin-Fixed, Paraffin-Embedded (FFPE)
HLA-DRA Antibody - Human Liver: Formalin-Fixed, Paraffin-Embedded (FFPE)
HLA-DRA Antibody - Human Small Intestine: Formalin-Fixed, Paraffin-Embedded (FFPE)
HLA-DRA Antibody - Human Thymus: Formalin-Fixed, Paraffin-Embedded (FFPE)
HLA-DRA Antibody - Human Kidney: Formalin-Fixed, Paraffin-Embedded (FFPE)
HLA-DRA Antibody - Human Liver: Formalin-Fixed, Paraffin-Embedded (FFPE)
1 of 4
2 of 4
3 of 4
4 of 4

PathPlus™ Monoclonal Mouse anti‑Human HLA‑DRA Antibody (clone TAL 1B5, IHC) LS‑B2858

PathPlus™ Monoclonal Mouse anti‑Human HLA‑DRA Antibody (clone TAL 1B5, IHC) LS‑B2858

Note: This antibody replaces LS-C49352
Antibody:
HLA-DRA Mouse anti-Human Monoclonal (TAL 1B5) Antibody
Application:
IHC, IHC-P, IHC-Fr
Reactivity:
Human
Format:
Unconjugated, Unmodified
Price
Catalog Number
$460
LS-B2858-0.1
Toll Free North America
206-374-1102
For Research Use Only

Overview

Antibody:
HLA-DRA Mouse anti-Human Monoclonal (TAL 1B5) Antibody
Application:
IHC, IHC-P, IHC-Fr
Reactivity:
Human
Format:
Unconjugated, Unmodified

Specifications

Description
HLA-DRA (Major histocompatibility complex, class II, DR alpha) is one of the HLA class II alpha chain paralogues. It is a heterodimer consisting of an alpha and a beta chain, both anchored in the membrane. It plays a central role in the immune system by presenting peptides derived from extracellular proteins. In immunohistochemistry, HLA-DRA has cytoplasmic expression in antigen presenting cells (APC) such as B lymphocytes, dendritic cells, macrophages, and is present in the lung, gastrointestinal tract, kidney, immune tissues, skin, breast and a few other organs throughout the body. References: The UniProt Consortium. Nucleic Acids Res. 47: D506-515 (2019); Nucleic Acids Res. 2016 Jan 4;44(D1):D733-45, PMID:26553804;
Target
Human HLA-DRA
Synonyms
HLA-DRA | HLA-DRA1 | MHC cell surface glycoprotein | MHC class II antigen DRA | MLRW
Host
Mouse
Reactivity
Human (tested or 100% immunogen sequence identity)
Clonality
IgG1 Monoclonal
Clone
TAL 1B5
Conjugations
Unconjugated
Purification
Purified IgG
Modifications
Unmodified
Immunogen
Bristol 8 separated alpha chain preparation
Specificity
HLA DR (TAL 1B5).
Applications
  • IHC
  • IHC - Paraffin (10 µg/ml)
  • IHC - Frozen
Performing IHC? See our complete line of Immunohistochemistry Reagents including antigen retrieval solutions, blocking agents ABC Detection Kits and polymers, biotinylated secondary antibodies, substrates and more.
Usage
Immunohistochemistry: LS-B2858 was validated for use in immunohistochemistry on a panel of 21 formalin-fixed, paraffin-embedded (FFPE) human tissues after heat induced antigen retrieval in pH 6.0 citrate buffer. After incubation with the primary antibody, slides were incubated with biotinylated secondary antibody, followed by alkaline phosphatase-streptavidin and chromogen. The stained slides were evaluated by a pathologist to confirm staining specificity. The optimal working concentration for LS-B2858 was determined to be 10 ug/ml.
Presentation
PBS, 0.02% Sodium Azide
Storage
Short term: store at 4°C. Long term: store at -20°C. Avoid freeze-thaw cycles.
Restrictions
For research use only. Intended for use by laboratory professionals.
Guarantee
This antibody carries the LSBio 100% Guarantee.
LSBio Guarantee
About HLA-DRA
P01903 NM_019111 NP_061984.2

Validation

HLA-DRA Antibody - Human Small Intestine: Formalin-Fixed, Paraffin-Embedded (FFPE)
Human Small Intestine: Formalin-Fixed, Paraffin-Embedded (FFPE)
Human Small Intestine: Formalin-Fixed, Paraffin-Embedded (FFPE)

HLA-DRA Antibody - Human Thymus: Formalin-Fixed, Paraffin-Embedded (FFPE)
Human Thymus: Formalin-Fixed, Paraffin-Embedded (FFPE)
Human Thymus: Formalin-Fixed, Paraffin-Embedded (FFPE)

HLA-DRA Antibody - Human Kidney: Formalin-Fixed, Paraffin-Embedded (FFPE)
Human Kidney: Formalin-Fixed, Paraffin-Embedded (FFPE)
Human Kidney: Formalin-Fixed, Paraffin-Embedded (FFPE)

HLA-DRA Antibody - Human Liver: Formalin-Fixed, Paraffin-Embedded (FFPE)
Human Liver: Formalin-Fixed, Paraffin-Embedded (FFPE)
Human Liver: Formalin-Fixed, Paraffin-Embedded (FFPE)

LSBio Ratings

PathPlus™ HLA-DRA Antibody (clone TAL 1B5) for IHC LS-B2858 has an LSBio Rating of
Publications (4.1)
Laboratory Validation Score (5)

Publications (2)

Assessment of the genetic basis of rosacea by genome-wide association study. Chang ALS, Raber I, Xu J, Li R, Spitale R, Chen J, Kiefer AK, Tian C, Eriksson NK, Hinds DA, Tung JY. The Journal of investigative dermatology. 2015 135:1548-1555. (IHC; Human)

Secukinumab, a novel anti-IL-17A antibody, shows low immunogenicity potential in human in vitro assays comparable to other marketed biotherapeutics with low clinical immunogenicity. Karle A, Spindeldreher S, Kolbinger F. mAbs. 2016 8:536-50. (WB; Human)

Customer Reviews (0)


Request SDS/MSDS

To request an SDS/MSDS form for this product, please contact our Technical Support department at:

Technical.Support@LSBio.com

Requested From: United States
Date Requested: 4/19/2024